



ecovatec  
SOLUTIONS INC



**Inspired  
Functional  
Ingredients to  
Innovate and  
Differentiate  
your brand**



# VISION

Ecovatec produces inspired functional ingredients to innovate and differentiate your brand

# MISSION

Engage in the global community to empower people to flourish by unleashing the high quality, naturally derived, bioactive ingredients stored in egg yolk

# CONTRIBUTION

We believe in passion, profitability, communication, accountability, growth, and exceptionality

# HDL

## Worldwide Heart Health



Over **300** Million Chinese<sup>1</sup>  
& Over **109** Million Americans<sup>2</sup> suffer from **high cholesterol**

- Are at risk of Cardiovascular Disease (**CVD**)
- Are taking or have been suggested to take statin **drugs**<sup>3</sup>
- **Why?**

# HDL

## The Problem

Heart disease accounts for **31%** of global deaths<sup>4</sup>

Statins are prescribed to lower LDL, but have major side effects such as blocking the heart's response to exercise<sup>5</sup>. They also don't target the effectiveness of the cholesterol transport system as a whole. This leads to a marginal effect on CVD mortality<sup>6</sup>.

Increasing number and quality of HDL is an effective method of reducing risk of CVD but it is difficult to accomplish.


## The Solution

Ecovatec has created a novel technology to naturally separate HDL from egg yolk. This allows you to eat more of the good component of egg yolk without all the bad cholesterol normally found in eggs.

Consuming egg HDL has been shown to improve overall cholesterol levels, increase the number and quality of HDL, and reduce LDL<sup>7</sup>.

This supports overall heart health!

# High Cholesterol – A Market Opportunity



Disrupt the statin market, \$19.2 bn in 2017 and growing. 70% of adults in US suffer from high LDL cholesterol.<sup>8</sup>




Enter the heart health supplement market, expected to reach \$29 bn by 2026.<sup>9</sup>



Meets consumer preferences for natural methods of lowering cholesterol without harmful side effects.



Enter the protein supplement market, valued at \$12.4 bn in 2016, growing at CAGR 6.3%.<sup>10</sup>



Egg white protein powder market is growing rapidly at a 31.2% CAGR. Expected to reach \$78 m market by 2025.<sup>11</sup>



Perfectly positioned for the growing keto trend – full of protein and healthy fat with 0 carbs



# Market Dynamics

There are tons of heart health supplements out there, so why is the market growing? What makes our product different?

Current supplements claim to lower triglycerides or LDL, but most don't work. Often the active ingredient isn't stable over time or is not well absorbed. Sometimes they do work, but they only work on the number of LDL particles, which is insufficient to reduce risk of cardiovascular disease.

Egg Yolk HDL is unique in that it **increases** HDL, reduces the **oxidation** of LDL (make them less bad for your arteries), AND reduces the **number** of LDL and triglycerides in the blood.<sup>7,12,13,14</sup>

It is also incredibly stable over time and starts to show amazing effects within 2 months!



# Products

## EcovaPure™ HDL



Ingredient to add to your nutraceutical or functional food product.

US \$100/kg

Capacity 35,000 kg/year

US \$3.5 million/year with 65% margin

1 kg = 500 eggs HDL

Only manufacturer!

**Target market:** nutraceutical and functional food companies

## Vitellus HDLevate™



A convenient, heart-healthy nutrition supplement.

US \$50/bottle

3 capsule serving = 1 egg yolk's HDL

Only the good cholesterol!

Impressive initial results!

**Target market:** Middle-Aged Adults, Aging Population, Diabetics, People with genetically high cholesterol

## Vitellus China EcovaPure™ HDL



A convenient, heart-healthy nutrition supplement.

1,518 RMB/package

2g x 90 tube package

2g = 1 egg yolk

Convenient, portable self-emulsifying powder can be added to drinks or food!

**Target market:** distributors and retailers in China

## HDL+ Protein Powders



A hi-tech complete meal, sports, or general nutrition supplement.

US \$150/30 servings

30 g serving:

3 eggs HDL

21g egg white protein

310/230 mg EPA/DHA

Keto friendly!

Heart Healthy HDL

Highly bioavailable omega 3 and antioxidants!

**Target market:** Athletes/ Active Adults, Keto/Paleo, Diabetics

# Initial Customer Results

## Patient X – Large Size

Month 1 = 9 pills/day

Month 2 = 6 pills/day

Month 3-4 = 3 pills/day

- Total Cholesterol – 25% ↓
- LDL C. – back within testing ↓
- HDL C. – 8.5% ↑
- Risk Ratio – 31% ↓
- Non-HDL C. – 31% ↓
- Triglycerides – 62% ↓

## Patient Y – Medium Size

Month 1 = 6 pills/day

Month 2 = 3 pills/day

- Total Cholesterol – 34% ↓
- LDL C. – 40% ↓
- HDL C. – 8% ↑
- Risk Ratio – 38% ↓
- Non-HDL C. – 40% ↓
- Triglycerides – 38% ↓







# Science Background

## High Density Lipoprotein and How they Work<sup>15</sup>

- HDL (High-Density Lipoproteins), the “good cholesterol”, remove cholesterol and Low-Density Lipoproteins (LDLs) from the blood and artery walls, preventing a buildup of “plaque”.
- “Plaque” buildup restricts blood flow in arteries, causing high blood pressure. Sometimes it completely close off smaller blood vessels, leading to heart attacks or strokes.
- HDL is anti-inflammatory, which increases blood flow and prevents particles from sticking to the artery walls.
- Studies show that increasing HDL levels reduces risk of heart attack, stroke, and peripheral artery disease





# Egg Yolk HDL

- Both LDLs and HDLs are found in egg yolk. This is why egg yolks are thought to be “high in cholesterol”. Ecovatec removes the “bad cholesterol” (LDLs) and leave in the good HDLs.
- HDL from egg yolk has been shown to:<sup>7,12,13,14</sup>
  - Improve cholesterol breakdown in body
  - Reduce overall cholesterol score
  - Stimulate natural HDL production
  - Reduce inflammation in arteries
  - Improve insulin effectiveness & reduce blood insulin levels
  - Support overall heart health
  - Improve the size distribution of blood HDL and LDL
- AND it contains antioxidants lutein and zeaxanthin!



## Why Is Microencapsulation on Trend in Nutraceuticals?



- IMPROVES BIOAVAILABILITY OF CORE INGREDIENTS
- Changes liquids into free-flowing solids (powders)
- Protects core materials from heat, moisture, air and light
- Masks the unpleasant taste/smell of core materials
- Extends the stability of sensitive core materials
- Improves compatibility between different materials within the same microcapsule
- Hinders the transfer rate or evaporation of core materials to the external environment
- Controls the release rate of core materials

# MyCellePro™

## The Problem

Many nutraceutical ingredients are not available to the body. For example only 8-10% of CBD taken orally is available for use in the blood<sup>1</sup>. <1% of curcumin is absorbed naturally as well. Lutein, astaxanthin, and other antioxidants have the same problem.

Other ingredients are difficult to work with due to fast oxidation and rancidity, such as fish oil.

Current microencapsulation technology use starches, whey protein, soy lecithin, or synthetic compounds – all of which have problems as microencapsulation materials.

## The Solution

Ecovatec has carefully isolated a novel microencapsulation material from egg yolk called MyCellePro™. It has been shown to effectively encapsulate many active ingredients and can be loaded up to 40-60%.

MyCellePro™ technology is natural, non-GMO, soy-free, clean label, heat stable, easy to work with, and comes in a powder form. Unlike most traditional microencapsulation technologies, you only need one ingredient to make the microencapsulation stable and bioavailable.



# Microencapsulation – Market Opportunity

## Specific Markets:

Omega 3 – 57.06 bn by 2025, 6% CAGR <sup>3</sup>

CBD Oil – 2.1 bn by 2020 <sup>4</sup>, 31% CAGR <sup>5</sup>

Curcumin – 130 m by 2025, 13% CAGR <sup>6</sup>

Coenzyme Q10 – 817m by 2022, 9.86% CAGR <sup>7</sup>

Lutein – 357.7m by 2022, 6% CAGR <sup>8</sup>


Astaxanthin – 555m in 2016 <sup>9</sup>, 4.8% CAGR <sup>10</sup>

Easier to work with than many traditional methods, makes many active ingredients easier to formulate into supplements


Perfectly positioned for the growing keto trend – technology consists of healthy fats and proteins, not carbs



The global microencapsulation market is expected to reach US 19.34 bn by 2025 with a CAGR of 13.6%.<sup>2</sup>



Meets consumer preferences for natural, clean, non-GMO ingredient labels



Patent pending technology with strong encapsulation ability up to 60% loading, increases bioavailability, masks taste/odor of actives, heat stable, powder form, and can increase shelf life stability.

# Market Dynamics

There are tons of supplements out there, so in order to differentiate themselves, more products are looking at the bioavailability of their active ingredients. Simply stated, bioavailability is the amount of an ingredient that can be taken up and used by the body. So what makes our technology different?

Current microencapsulation technology use starches, whey protein, soy lecithin, or synthetic compounds – all of which have problems as microencapsulation materials. Some aren't clean label, some don't improve bioavailability at all, some must exist in liquid form and can't be applied to fortified foods. Many only load up to 30-35%.

Ecovatec's MyCellePro™ technology exists naturally in eggs, takes only 1 ingredient, is clean-label, improves bioavailability, has higher loading capacities, can exist in powder form, and can be easily incorporated into health foods and beverages. It is basically, a one-stop-shop!



# Product Applications

## CBD Supplement



Challenges: Oral bioavailability of CBD has been estimated at between 9-13%, can be improved 3-4x with microencapsulation

### Market:

USD 2.1 bn by 2020<sup>4</sup>,  
CAGR 31% (until 2022) <sup>5</sup>

Soluble powder needed for beverage, baking, supplement applications

Currently very few competitors

**Target market:** Age 35-64; Educated; Pain management, Insomnia, Depression, Anxiety

## Curcumin Supplement



Challenges: insoluble in water, hard to absorb, is rapidly metabolized, and rapidly eliminated from the body

### Market:

USD 130 m by 2025, CAGR 13.3%<sup>6</sup>

23 million in North America

Consumers know importance of bioavailability

Current tech: soy, synthetics, starch, cellulose

**Target market:** Middle-Aged Adults, Aging Population, Alzheimer's prevention, heart disease, cancer, arthritis, depression

## Omega 3 Supplement



Challenges: goes rancid quickly, aftertaste, hard to formulate with oil (few powder versions available), need emulsifier if adding to food/smoothies.

### Market:

USD 57.06 bn by 2025,  
CAGR 6.0%<sup>3</sup>

Microencapsulation trend just starting, very few successfully microencapsulate fish oil.

### **Target market:**

All ages (child through elderly), dementia prevention, heart disease, healthy development, arthritis, depression

## Vitamin A, D, E, K Supplements



Challenges: insoluble in water, hard to absorb.  
Necessary for many biological functions – bone health, immune system, cell growth, etc.

### Market:

USD 81 bn by 2025,  
6.6% CAGR<sup>11</sup>

Vitamin D alone – 1.7 bn by 2025, fastest growth<sup>12</sup>

**Target market:** All ages (child through elderly), dementia prevention, heart disease, healthy development, arthritis, depression



# Sample Formulations

## Brain Lecithin™ (Capsules); Price: 80 CAD

- A 1 sachet or 3 pill serving of MyCellePro™ Brain Formula contains omega-3 fatty acids and ginkgo biloba microencapsulated in egg yolk isolate micelles full of choline.
- Health Claims:
  - Helps to enhance cognitive function in adults
  - Helps to enhance memory in adults
  - Helps to support peripheral circulation
  - Helps to support liver function



## Liver Lecithin™ (Capsules); Price: 80 CAD


- A 1 sachet or 3 pill serving of MyCellePro™ Liver Formula contains omega-3 fatty acids and milk thistle microencapsulated in egg yolk isolate micelles full of choline.
- Health Claims:
  - Traditionally used in Herbal Medicine as a hepatoprotectant/ liver protectant
  - Used in Herbal Medicine to help relieve digestive disturbances/dyspepsia
  - Helps support cognitive health and/or brain function
  - Helps to support liver function





# Microencapsulation Science

- Many ingredients that would be helpful to our health are not “water-soluble”. They are fat-soluble, meaning that they are NOT easily absorbed from the water-based intestinal fluid.
- Your body releases bile salts into the intestine in order to create microemulsions when fats are ingested. This allows \*some\* of the fat-soluble products to be absorbed.
- Microemulsions = oil droplets in water that are surrounded by “surfactants” that stabilize them.
- Microemulsions can be dried into a powder while keeping the small “droplet size”, creating microencapsulation.
- Fat-soluble active ingredients such as CBD, curcumin, omega-3s, astaxanthin, biotin, and fat soluble vitamins A,D,E,K etc. can be dissolved into the oil, which is then microencapsulated.
- This way, bile salts aren’t needed, and the process is more efficient at absorbing \*more\* of the active ingredient.



# MyCellePro™ – Skin Applications

Component of MyCellePro™	% of Total	Skin Effect <sup>13, 14</sup>
Phospholipids	> 20%	<ul style="list-style-type: none"> <li>- Skin barrier repair</li> <li>- Anti-inflammatory</li> <li>- Permeability enhancer</li> </ul>
Omega 9 Fatty Acid (Oleic Acid)	37.6%	<ul style="list-style-type: none"> <li>- It disrupts the skin barrier to increase permeability, allowing fatty acids to moisturize deeper into the skin</li> <li>- Induced faster wound closure compared to Omega 3 and 6 fatty acids</li> <li>- Activates regeneration of the lipid barrier</li> <li>- Reduces inflammation</li> <li>- Excellent for skin softening and moisturizing</li> </ul>
Omega 6 Fatty Acid (Linoleic Acid, Derivatives)	11.3%	<ul style="list-style-type: none"> <li>- Reinforces the skin barrier, excellent when paired with oleic acid which disrupts the skin barrier. The combination allows the lipids to penetrate deep into the skin, but then re-seal itself keeping the moisture in and protecting the skin.</li> <li>- Anti-inflammatory</li> <li>- It tricks skin into producing less oil as it is a component of skin oil</li> <li>- Clears blocked pores and prevents acne</li> <li>- Used in the structure of cell membranes</li> <li>- May help with treatment of atopic eczema</li> </ul>
Cholesterol	1.8%	<ul style="list-style-type: none"> <li>- Helps skin regain elasticity and plumpness</li> <li>- Reinforces skin barrier and replaces lipid protection layer (which decreases with age)</li> <li>- Excellent for sensitive and dry skin</li> </ul>
Omega 3 Fatty Acid (DHA, EPA)	0.5%	<ul style="list-style-type: none"> <li>- Treats and prevents skin problems such as psoriasis and acne</li> <li>- Natural sunscreen properties</li> <li>- Decreases melanin synthesis</li> <li>- Stimulates the healing process</li> </ul>
Antioxidants	<0.1%	<ul style="list-style-type: none"> <li>- Reduces oxidative stress that leads to ageing (anti-ageing effects)</li> </ul>



# MyCellePro™

**US\$100** per kg; plant capacity 57,000 kg annually  
\$5.7 million per year with **>50%** margin

- Egg yolks naturally contain microemulsions in the form of very small (~50nm) “micelles”.
- These are oil droplets coated in phospholipids, cholesterol with proteins attached for added stability.
- Ecovatec has naturally isolated these micelles in “MyCellePro™”
- Proven capability to add active ingredients into the micelles which can then be dried into a powder.
- Loading of 40% - 60% is possible.



# Phosvitin

What if we could disrupt the \$10bn iron and calcium supplement markets?

Breakthrough technology to manufacture **phosvitin** protein





# Phosvitin

## The Problem

Current **iron supplements** have major side effects such as: constipation, stomach pain, nausea and vomiting. This is due to the **oxidative stress** caused by un-absorbed iron as it passes through the digestive tract and results because the body can't absorb the iron<sup>1</sup>. Even "chelated" iron has low absorptivity.<sup>2</sup>

Current **calcium supplements** work to increase blood calcium. That is, the calcium is absorbed. However, this increased blood calcium doesn't translate into increased bone density and can lead to calcification in the arteries.<sup>3</sup>

Current **eczema treatments** have major side effects, cannot be taken long term for a variety of reasons, or are not effective.

## The Solution

Scientists have been studying **phosvitin protein** for years, but have been unable isolate it on a commercial scale.<sup>4-11</sup> The global research community has published extensively on the applications of phosvitin peptides for **increasing iron and calcium absorption** among other bioactive capabilities, such as reducing inflammation and excessive cell growth in skin conditions such as **eczema and psoriasis**.<sup>4-11</sup>

Ecovatec is the first company to extract phosvitin peptides on a commercial scale, using green technology to ensure the bioactivity remains intact.

# Market Opportunity

Iron Supplement  
Calcium Supplement  
Atopic Dermatitis/Eczema



Iron Supplement Market  
retail – US\$ 3.023 Bn  
Projected at US\$ 6.354 Bn by 2025.<sup>12</sup>



Current scientific market pricing for Phosvitin is over \$3M USD/kg.<sup>13</sup>  
At Ecovatec pricing of \$40k USD/kg the plant capacity of 1,600 kg per year translates into \$64M in potential revenue.



Meets consumer preferences for natural, clean, non-GMO ingredient labels



The Calcium Market retail – US\$ 6.9 Bn (5% CAGR).<sup>14</sup>

75% of adult Americans are calcium deficient. Currently, no supplements increase bone density.<sup>3</sup>



Phosvitin peptides have also been shown to improve eczema symptoms<sup>15</sup>, which affects 10% of people at some point in their lives. Eczema Market retail – US\$6.4 Bn (6.6% CAGR by 2022)<sup>16</sup>



Our process for creating phosvitin peptides is patent-pending!

\* Currency in \$USD

# Product Applications

## Calcium Supplement



Challenges: increased blood calcium isn't able to increase bone density and can lead to calcification in the arteries.

Phosvitin peptides will provide bone density increases rather than just increasing blood calcium.<sup>8</sup>

**Target market:** Post-Menopausal women; Aging Population, Children

## Iron Supplement



Challenges: major side effects such as: constipation, dark stools, stomach pain, nausea and vomiting.

Reduced iron quantity  
Increase absorption rates  
Reduced digestive side effects

**Target market:** Women (& Pregnant Women); Athletes/Active Adults

## Eczema Cream



Challenges: current treatments are not effective and have huge side effects and they can't be taken long term.

Phosvitin creams have been tested on eczema with good results and can be taken indefinitely, with no harmful side effects.<sup>15</sup>

**Target market:** Children through Adults suffering from eczema and/or atopic dermatitis

# Sample Formulations

## Iron Supplement™; Price: 30 CAD

- Iron-phosvitin peptide chelate product using ferrous sulfate.
- Health Claims: Helps to...
  - form red blood cells and helps in their proper function
  - prevent iron deficiency (anemia) and associated tiredness and fatigue



## Calcium Supplement™; Price: 50 CAD

- Calcium-phosvitin peptide chelate product using calcium carbonate
- Health Claims:
  - Helps in the development and maintenance of bones and teeth
  - As part of a healthy diet (when taken with Vitamin D) may help prevent bone loss/osteoporosis
  - Helps support bone health.







# Phosvitin Science

Global research community

→ hundreds published papers

**Phosvitin (PV) and Phosvitin Peptides (PVP):**<sup>4-11,15</sup>

- Increase iron absorption
- Increase calcium absorption and transformation to bone mineral
- Excellent anti-oxidants
- Exhibit anti-bacterial, anti-viral, and toxin-neutralizing behaviours including killing the bacteria causing sepsis, and
- Cytotoxic to liver, cervical, lung, stomach, breast and larynx cancer cells, in vitro



# Breakthrough Technology



Liquid  
Egg Yolk



Pure Water




Green  
Separation




High Value  
Bioactive  
Proteins


## Typical Processor



Powdered  
Egg Yolk



Harsh  
Solvents



High Pressure/  
Temperature  
Solvent Extraction



Low Value  
Denatured  
Proteins

# Competitive Advantage

Not only does Ecovatec use patent-pending breakthrough technology to isolate bioactive egg components with greater purity and efficiency than competitors, we are also the only producers of these novel products.

High Density Lipoprotein (HDL) – patent pending heart healthy ingredient

Phosvitin Peptides (PV & PVP) – patent pending bioactive proteins

MyCellePro – patent pending nano/micro encapsulation technology ingredient

Emulsova – patent pending food grade emulsifier and lecithin supplement

# Achievements to Date

12,000-square-foot state-of-the-art pharmaceutical-grade processing plant located in Abbotsford, B.C.



US Distributor - investment in ESI with agreement to fund and perform clinical trials for HDL and MyCellePro products



New phosvitin eczema cream, egg oil skin therapy, and HDL and MyCellePro supplements developed



Patent-pending intellectual property for both processes and products



Retail partner Vitellus Health making sales of HDLevate and Egg Oil worldwide through online store and Amazon marketplace



HDL Clinical Study commenced





# Road Map




## Q4 2019

- Finish financing round
- Start HDL clinical



## Q2 2020

- Initial results from clinical testing
- Focus on sales
- MyCellePro Expansion – new Vitellus China Vitamin/Mineral product line introduced to Asian Market



## Q2 2019

- Signed deal with distributor
- Start preparation for HDL clinical study
- LOI with Chinese Distributor
- LOI with LeanLife Health for high omega-3 oil production and powdered high omega-3 oil



## Q1 2020

- See initial HDL trial results
- Start clinical testing for other products: microencapsulation, CBD, PV-Iron, PV-Skin
- Chinese partnership



# Use of Proceeds

Raise: CA \$2.5 M

PV Iron Supplement Clinical Trial	400k
-----------------------------------	------

PV Skin Application Testing	100k
-----------------------------	------

MyCellePro Microencapsulation Testing	100k
---------------------------------------	------

HDL China Product Testing	100k
---------------------------	------

HDL China FDA Approvals	100k
-------------------------	------


CBD JV Partnership Manufacturing Facility	125k
---	------

CBD Absorption Study	100k
----------------------	------

CBD Product Development	75k
-------------------------	-----

Operating Capital	1,150k
-------------------	--------

Patents	250k
---------	------



# Financial Projections\*

Forecast Year	Revenue	Production Costs	Gross Profit	Gross Margin	Overhead	Clinical Trials	EBITDA	EBITDA Margin	Net Profit	Capital Improvement
2019	\$0	\$94,747	-\$94,747		\$194,435	\$0	-\$289,181		-\$569,181	\$0
2020	\$1,710,688	\$1,205,641	\$505,047	30%	\$1,443,208	\$400,000	-\$1,338,161	-78%	-\$1,618,161	\$0
2021	\$11,450,539	\$6,817,856	\$4,632,682	40%	\$2,411,906	\$400,000	\$1,820,776	16%	\$1,540,776	\$1,000,000
2022	\$31,261,803	\$10,528,318	\$20,733,485	66%	\$3,423,849	\$0	\$17,309,636	55%	\$14,038,442	\$0

\* Currency in CAD

\* Projections are conservative and are based on current capacity with a mix of Ecovatec products. With small capital improvements it is easy to scale up and meet growing demand for any one of these products.

\* Annual revenues in excess of CA \$50M can be achieved by 2024 with minimal additional capital and market penetration.

# Capital Structure

## Private Canadian Company

- Total Issued Shares: 55.36 M Shares
- Stock Options 2.01 M Shares
- Warrants 3.98 M Shares
- Total Shares Fully Diluted 61.35 M Shares

## Financing Terms

- Total Issued Shares 55.36 M Shares
- Treasury (with SR&ED) \$150 k
- Current Financing
  - 6.25 M Shares
  - \$2.5 M
  - \$0.40/share
- Post Financing 61.61 M Shares
- Pre/Post Financing Market Cap \$22.1 M / \$24.6 M

- Burn rate: ~ CA \$50K / month

Currency in CAD



# Our Team



**Drew Perrin**, B.A.Sc.Eng., B.Ed.  
CEO, Director

Business leader, new product developer, energy management, product conceptualization, new product design, commercialization



**Chris Nichols**, B.Sc.  
President, Director

Large multinational food companies, complex on/off site leadership, Lean Six Sigma, cost optimization, operational performance



**Rick Gagner**, B.BA  
Chief Financial Officer

Strong reputation through 30 years of business leadership, held numerous C-Suite positions, recently CEO of Rhema Health Products Inc.



**West Ma**, President, Vitellus China  
ESI Business Development

30 + years of experience in international sales and marketing, project management, M&A, and new business development across multiple verticals.



**Alex Holdcroft**, M.M., B.Sc.  
Product Manager

Biologist, Masters in Management science communication, research, content writing, project management, market strategy, website coordinator



**Harry ten Haaf**,  
Production Manager

# Advisors



**Dr. Zachary S. Wochok**, Ph.D, M.S., B.Sc.  
Strategic Advisor

Management consultant, numerous C-Suite and board positions, large multinational companies, food ingredients, ag-biotech, biologist.



**Dr. Stewart Ritchie**, Ph.D., M.S., D.V.M., Diplomate  
Advsiior

President of Canadian Poultry Consultants and S.J. Ritchie Research Farms. Previously President of the American Association of Avian Pathologists (AAAP). Developed Platinum Brooding® Program.

# Summary

- HDL from Egg Yolk can disrupt the statin market
- MyCellePro novel microencapsulation technology has applications in multiple supplement markets
- Phosvitin Peptides disrupt iron, calcium, and eczema markets
- Current financing of CA \$2.5 M funds Ecovatec to positive cash flow achieving HDL, MyCellePro, and PVP revenue and market penetration into Asia
- 2019 Q2 start HDL clinical studies prove effectiveness and dosage → demonstrate results by 2020 Q2
- 2020 Q1 start clinical testing for microencapsulation products
- 2020 Q2 expand MyCellePro – new Vitellus China Vitamin/Mineral product line introduced to Chinese Market

# HDL References

- <sup>1</sup> [https://academic.oup.com/eurheartjsupp/article/18/suppl\\_F/F2/2197105](https://academic.oup.com/eurheartjsupp/article/18/suppl_F/F2/2197105)
- <sup>2</sup> [https://www.cdc.gov/cholesterol/cholesterol\\_education\\_month.htm](https://www.cdc.gov/cholesterol/cholesterol_education_month.htm)
- <sup>3</sup> <https://www.acsh.org/news/2015/12/04/cdc-study-reveals-that-too-few-americans-are-on-statins>
- <sup>4</sup> <https://apfoodonline.com/industry/a-finger-on-the-pulse-trends-in-heart-health-supplements/>
- <sup>5</sup> <https://universityhealthnews.com/daily/heart-health/statins-side-effects-exercise-benefits-are-blocked/>
- <sup>6</sup> DuBroff, R., et al. "Cholesterol confusion and statin controversy". *World J Cardiol*, vol. 7, no. 7, 2015, pp. 404-409
- <sup>7</sup> Clayton, Zachary S., et al. "Egg consumption and heart health: A review." *Nutrition*, vol. 37, 2017, pp. 79–85., doi:10.1016/j.nut.2016.12.014.
- <sup>8</sup> <http://www.statinnation.net/blog/2017/10/4/cholesterol-lowering-industry-still-worth-more-than-19-billion-and-increasing>
- <sup>9</sup> <https://www.prnewswire.com/news-releases/heart-health-supplements-market-to-reach-us-29-000-mn-by-2026-persistence-market-research-898168896.html>
- <sup>10</sup> <https://www.grandviewresearch.com/industry-analysis/protein-supplements-market>
- <sup>11</sup> <https://www.marketwatch.com/press-release/egg-white-protein-powder-market-size-rising-at-312-cagr-to-2025-2019-04-10>
- <sup>12</sup> Eftekhari, S., et al. "The Prevention and Treatment Effects of Egg Yolk High Density Lipoprotein on the Formation of Atherosclerosis Plaque in Rabbits." *Iranian Journal of Basic Medical Sciences*, vol. 18, no. 4, 2015, pp. 343-349.
- <sup>13</sup> Blesso, Christopher N., et al. "Whole egg consumption improves lipoprotein profiles and insulin sensitivity to a greater extent than yolk-free egg substitute in individuals with metabolic syndrome." *Metabolism*, vol. 62, no. 3, 2013, pp. 400–410., doi:10.1016/j.metabol.2012.08.014.
- <sup>14</sup> Greene, C., et al. "Plasma LDL and HDL characteristics and carotenoid content are positively influenced by egg consumption in an elderly population". *Nutr Metab*, vol 3, no: 6, 2006,
- <sup>15</sup> <https://watchlearnlive.heart.org/?moduleSelect=hdldl>



# MyCellePro™ References

<sup>1</sup> Cherniakov, Irina, Dvora Izgelov, Abraham J. Domb, and Amnon Hoffman. "The Effect of Pro NanoLipospheres (PNL) Formulation Containing Natural Absorption Enhancers on the Oral Bioavailability of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in a Rat Model." *European Journal of Pharmaceutical Sciences* 109 (2017): 21-30. doi:10.1016/j.ejps.2017.07.003.

<sup>2</sup> <https://www.grandviewresearch.com/industry-analysis/microencapsulation-market>

<sup>3</sup> <https://www.prnewswire.com/news-releases/omega-3-supplements-market-size-worth-usd-57-06-billion-by-2025-hexa-research-832514526.html>

<sup>4</sup> [naturallysplendid.com/resources/2017/01/cbd-market-estimated-grow-2-1b-2020-report-finds-hemp-derived-cbd-estimated-account-450-million/](http://naturallysplendid.com/resources/2017/01/cbd-market-estimated-grow-2-1b-2020-report-finds-hemp-derived-cbd-estimated-account-450-million/)

<sup>5</sup> <https://www.technavio.com/report/global-cbd-oil-market-analysis-share-2018>

<sup>6</sup> <https://www.grandviewresearch.com/press-release/curcumin-market>

<sup>7</sup> <https://www.technavio.com/report/global-coenzyme-q10-supplements-market-analysis-share-2018>

<sup>8</sup> <https://www.marketsandmarkets.com/PressReleases/lutein.asp>

<sup>9</sup> <https://www.grandviewresearch.com/industry-analysis/global-astaxanthin-market>

<sup>10</sup> <https://www.gminsights.com/industry-analysis/astaxanthin-market>

<sup>11</sup> <https://www.persistencemarketresearch.com/market-research/vitamins-supplements-market.asp>

<sup>12</sup> <https://www.prnewswire.com/news-releases/vitamin-d-market-worth-1-7-billion-by-2025--exclusive-report-by-marketsandmarkets-300852359.html>

<sup>13</sup> Zielinska, Aleksandra, and Izabela Nowak. "Fatty Acids in Vegetable Oils and Their Importance in Cosmetic Industry." *Chemik*, vol. 68, no. 2, 2014, pp. 103–110.

<sup>14</sup> Lin, Tzu-Kai, et al. "Anti-Inflammatory and Skin Barrier Repair Effects of Topical Application of Some Plant Oils." *International Journal of Molecular Sciences*, vol. 19, no. 1, 2017, p. 70., doi:10.3390/ijms19010070.

# Phosvitin References

- <sup>1</sup> Tiwari, Amit Kumar Mani, Abbas Ali Mahdi, Sudarshna Chandyan, Fatima Zahra, Madan Mohan Godbole, Shyam Pyari Jaiswar, Vinod Kumar Srivastava, and Mahendra Pal Singh Negi. "Oral Iron Supplementation Leads to Oxidative Imbalance in Anemic Women: A Prospective Study." *Clinical Nutrition* 30, no. 2 (2011): 188–93. <https://doi.org/10.1016/j.clnu.2010.08.001>.
- <sup>2</sup> <https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/>
- <sup>3</sup> Tai, Vicky, William Leung, Andrew Grey, Ian R. Reid, and Mark J. Bolland. "Calcium Intake and Bone Mineral Density: Systematic Review and Meta-analysis." *Bmj*, 2015. doi:10.1136/bmj.h4183.
- <sup>4</sup> Mudiyansele and Himali. "Production and Characterization of Phosphopeptides from Egg Yolk Phosvitin." Graduate Thesis and Dissertations. 2012. Paper 12451.
- <sup>5</sup> Samaraweera et al. "Egg Yolk Phosvitin and Functional Phosphopeptides-Review." *Journal of Food Science*, vol. 76, no. 7, Jan. 2011, doi:10.1111/j.1750-3841.2011.02291.x.
- <sup>6</sup> Samaraweera et al. "Characterisation of phosvitin phosphopeptides using MALDI-TOF mass spectrometry." *Food Chemistry*, vol. 165, 2014, pp. 98–103., doi:10.1016/j.foodchem.2014.05.098.
- <sup>7</sup> Ren, J., et al. "Preparation and characterization of phosphopeptides from egg yolk phosvitin." *Journal of Functional Foods*, vol. 18, 2015, pp. 190–197., doi:10.1016/j.jff.2015.07.007.
- <sup>8</sup> Choi, I, et al. "Effectiveness of phosvitin peptides on enhancing bioavailability of calcium and its accumulation in bones." *Food Chemistry*, vol. 93, no. 4, 2005, pp. 577–583., doi:10.1016/j.foodchem.2004.10.028.
- <sup>9</sup> Zhong, Q., et al. "Phosvitin phosphopeptide preparation using immobilised trypsin and enhancing calcium absorption in growing rats." *Czech Journal of Food Sciences*, vol. 34, no. No. 4, May 2016, pp. 325–331., doi:10.17221/425/2015-cjfs.
- <sup>10</sup> Zhang, Xiaowei, et al. "Role of phosphorylation of phosvitin in the phase transformation of mineralization." *International Journal of Biological Macromolecules*, vol. 101, 2017, pp. 712–718., doi:10.1016/j.ijbiomac.2017.03.158.
- <sup>11</sup> Zhang, Xiaowei, et al. "Acceleration of the initial phase transformation of mineralization by phosvitin." *Journal of Crystal Growth*, vol. 409, 2015, pp. 44–50., doi:10.1016/j.jcrysgr.2014.10.001.
- <sup>12</sup> Credence Research. "Global Iron Supplements Market Is Expected To Reach US\$ 6,353.9 Mn By 2025: Changing Lifestyle Along With Shift In Dietary Habits Of Consumers, Is Boosting Iron Supplement Market." Market Research Reports. Accessed January 14, 2019. <https://www.credenceresearch.com/press/global-iron-supplements-market>.
- <sup>13</sup> <https://www.sigmaaldrich.com/catalog/product/sigma/p1253?lang=en&region=CA>
- <sup>14</sup> Nutrition Business Journal. US Supplement Market Share by Condition. 2015.
- <sup>15</sup> Patent No: US 7,982,008 B2 Issued to Dr. David Bar-Or.
- <sup>16</sup> <https://www.grandviewresearch.com/press-release/global-atopic-dermatitis-drugs-market>



ecovatec  
SOLUTIONS INC



**Inspired  
Functional  
Ingredients to  
Innovate and  
Differentiate  
your brand**

# Forward Looking Statements (1/2)

Statements contained in this presentation that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “Forward-Looking Information”) within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward Looking Information includes, but is not limited to, statements relating to the timing, availability and amount of financings; expected use of proceeds; business objectives; the timing and costs of future activities on the Corporation’s properties; success of development activities; planned expenditures and budgets and the execution thereof; evaluation of the potential impact of future accounting changes; estimates concerning recovery of accounts receivable, stock-based compensation and carrying value of properties. In certain cases, Forward-Looking Information can be identified by the use of words and phrases such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. The Corporation has applied several material assumptions, including, but not limited to, the assumption that the Offering will be completed and that any additional financing needed will be available on reasonable terms; the exchange rates for the U.S. and Canadian currencies in 2019 and 2020 will be consistent with the Corporation’s expectations. Other assumptions are discussed throughout this presentation and Forward-Looking Information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Corporation to be materially different from any future results, performance or achievements expressed or implied by the Forward-Looking Information. (...continued)



# Forward Looking Statements (2/2)

Such risks and other factors include, among others, risks related to the completion of financings and the use of proceeds; operations and contractual obligations; changes in development programs based upon results of exploration; changes in estimated mineral reserves or mineral resources, future prices of metals; availability of third party contractors; availability of equipment; failure of equipment to operate as anticipated; accidents, effects of weather and other natural phenomena and other risks associated with the technology and alternative energy industries; environmental risks, including environmental matters under U.S. federal rules and regulations; impact of environmental remediation requirements and the terms of existing and potential consent decrees on the financing; fluctuations in currency prices; the Corporation's dependence on fuel sources; currency fluctuations; changes in environmental laws and regulations and changes in the application of standards pursuant to existing laws and regulations which may increase costs of doing business and restrict operations; risks related to dependence on key personnel; and estimates used in financial statements proving to be incorrect. Although the Corporation has attempted to identify important factors that could affect the Corporation and may cause actual actions, events or results to differ materially from those described in Forward-Looking Information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on Forward-Looking Information. Except as required by law, the Corporation does not assume any obligation to release publicly any revisions to Forward-Looking Information contained in this presentation to reflect events or circumstances after the dates thereof or to reflect the occurrence of unanticipated events.